Contact
Bone Therapeutics

Pipeline

Bone Therapeutics has developed an allogeneic, off-the-shelf bone cell therapy product, ALLOB, and an enhanced viscosupplement, JTA-004, which target 3 bone indications in clinical trials and offer the potential for additional product extensions.

Pipeline

In addition, Bone Therapeutics is conducting preclinical research on next generation product candidates such as combined cell-matrix products for large bone defects and maxillofacial applications.